Hospital
Bristol Bay Area Health Corporation
Bristol Bay Area Health Corporation was paid $37.01M by Medicaid between Jan 2018 and Dec 2024, across 154 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 18% of everything it billed.
33Billing provider infoBRISTOL BAY AREA HEALTH CORPORATION
DILLINGHAM, AK 99576
DILLINGHAM, AK 99576
33aNPI1831270842assigned 10/17/2006
33bProvider typeCritical Access Hospital
28Total paid$37.01M
24GClaims193,595
24DCodes billed154
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Alaska
Rank by total paid#3 of 8
Median peer was paid$17.70M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CLARK, ROBERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 45,865 | $5.28M | |
| 2019 | 30,433 | $5.02M | |
| 2020 | 21,934 | $4.04M | |
| 2021 | 22,183 | $4.58M | |
| 2022 | 24,150 | $5.98M | |
| 2023 | 25,579 | $5.97M | |
| 2024incomplete | 23,451 | $6.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 18% | 28,548 | 20,297 | $6.72M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 20,806 | 15,810 | $4.65M |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 6.4% | 3,049 | 2,781 | $2.38M |
| 80053 | Comprehensive metabolic panel | 6.1% | 6,348 | 5,200 | $2.27M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4.1% | 2,925 | 2,167 | $1.51M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.3% | 7,080 | 3,562 | $1.21M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.0% | 4,577 | 3,931 | $1.10M |
| 99442 | 2.9% | 1,615 | 1,335 | $1.06M | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | 2.4% | 1,269 | 1,192 | $896K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.4% | 9,708 | 5,666 | $878K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 2.2% | 1,123 | 1,083 | $824K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.1% | 5,410 | 4,760 | $795K |
142 more codes
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.9% | 4,557 | $714K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.9% | 1,492 | $696K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.8% | 1,645 | $652K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.7% | 1,972 | $637K |
| 80305 | 1.7% | 2,782 | $631K | |
| 36415 | Collection of venous blood by venipuncture | 1.5% | 5,151 | $555K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.5% | 1,486 | $544K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.3% | 3,145 | $479K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 1,360 | $479K |
| 87070 | 1.2% | 864 | $451K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.2% | 1,059 | $428K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.0% | 1,122 | $376K |
| 99443 | <1% | 558 | $367K | |
| 81025 | <1% | 2,012 | $357K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 1,104 | $342K |
| 86592 | <1% | 1,580 | $318K | |
| 99441 | <1% | 511 | $316K | |
| 87081 | <1% | 720 | $294K | |
| 81001 | <1% | 3,430 | $287K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,124 | $242K |
| 99284 | Emergency room visit (serious) | <1% | 3,175 | $199K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 562 | $169K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,804 | $154K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 391 | $152K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 249 | $150K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,534 | $147K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 209 | $143K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,181 | $139K |
| 92015 | Determination of refractive state | <1% | 2,583 | $133K |
| 85018 | <1% | 743 | $128K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 461 | $121K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 190 | $120K |
| 99285 | Emergency room visit (most serious) | <1% | 1,345 | $109K |
| 87400 | <1% | 406 | $102K | |
| 92504 | <1% | 380 | $99K | |
| 87210 | <1% | 481 | $97K | |
| 80061 | Lipid panel | <1% | 922 | $94K |
| 92567 | <1% | 595 | $80K | |
| 83655 | <1% | 212 | $75K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 3,210 | $67K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 227 | $64K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,880 | $61K |
| 81003 | <1% | 130 | $57K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 312 | $51K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 115 | $48K |
| 92553 | <1% | 52 | $41K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 45 | $41K |
| 86703 | <1% | 1,368 | $39K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 117 | $38K |
| 90686 | <1% | 567 | $37K | |
| 92557 | <1% | 199 | $36K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 644 | $35K |
| J3490 | Unclassified drugs | <1% | 578 | $32K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 146 | $27K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,269 | $26K |
| 86850 | <1% | 41 | $26K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,352 | $22K |
| 90647 | <1% | 253 | $22K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 114 | $20K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 27 | $20K |
| 85027 | <1% | 451 | $20K | |
| S9484 | Crisis intervention mental health services, per hour | <1% | 76 | $19K |
| 85014 | <1% | 305 | $19K | |
| 86580 | <1% | 129 | $17K | |
| 86803 | <1% | 1,298 | $15K | |
| T1016 | Case management, each 15 minutes | <1% | 63 | $15K |
| 97161 | <1% | 489 | $15K | |
| 90633 | <1% | 160 | $15K | |
| 82962 | <1% | 48 | $12K | |
| 86140 | <1% | 278 | $10K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 14 | $10K |
| 81002 | <1% | 29 | $9K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 47 | $9K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 480 | $9K |
| 90715 | <1% | 325 | $9K | |
| 71045 | Radiologic examination, chest; single view | <1% | 192 | $8K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 29 | $8K |
| 92552 | <1% | 12 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 28 | $7K |
| 85610 | <1% | 63 | $7K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 72 | $7K |
| 82570 | <1% | 136 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 65 | $5K |
| 73130 | <1% | 28 | $5K | |
| 99000 | <1% | 6,463 | $5K | |
| 92100 | <1% | 55 | $4K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 83 | $4K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 794 | $4K |
| 83690 | <1% | 668 | $3K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 23 | $3K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 225 | $3K |
| 99152 | <1% | 19 | $3K | |
| 83540 | <1% | 29 | $2K | |
| 90696 | <1% | 87 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 55 | $2K |
| 83735 | <1% | 638 | $2K | |
| 87806 | <1% | 359 | $2K | |
| A0180 | Non-emergency transportation: ancillary: lodging-recipient | <1% | 15 | $2K |
| 92250 | <1% | 28 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,120 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 25 | $2K |
| 87077 | <1% | 207 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 91 | $1K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 35 | $1K |
| 90723 | <1% | 154 | $808.00 | |
| 90670 | <1% | 369 | $710.00 | |
| 87420 | <1% | 15 | $682.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 97 | $682.00 |
| 90685 | <1% | 14 | $653.00 | |
| 82043 | <1% | 28 | $653.00 | |
| 86704 | <1% | 91 | $653.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 2,097 | $0.00 |
| 87186 | 0% | 720 | $0.00 | |
| 90707 | 0% | 253 | $0.00 | |
| 90734 | 0% | 158 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 81 | $0.00 |
| 84100 | 0% | 85 | $0.00 | |
| 86900 | 0% | 41 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 31 | $0.00 |
| 82248 | 0% | 13 | $0.00 | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 0% | 24 | $0.00 |
| 90651 | 0% | 201 | $0.00 | |
| 84484 | 0% | 244 | $0.00 | |
| 80320 | 0% | 827 | $0.00 | |
| 85730 | 0% | 26 | $0.00 | |
| 87340 | 0% | 226 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 35 | $0.00 |
| 83605 | 0% | 49 | $0.00 | |
| 0352U | 0% | 172 | $0.00 | |
| 90716 | 0% | 176 | $0.00 | |
| G0378 | Hospital observation service, per hour | 0% | 57 | $0.00 |
| 90680 | 0% | 39 | $0.00 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 49 | $0.00 |
| 90474 | 0% | 25 | $0.00 | |
| 86901 | 0% | 41 | $0.00 | |
| Q3014 | Telehealth originating site facility fee | 0% | 13 | $0.00 |
| 90688 | 0% | 13 | $0.00 | |
| 97802 | 0% | 28 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 24 | $0.00 |
| 87522 | Neg quan hep c or qual rna | 0% | 12 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 14 | $0.00 |
| 83550 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCLARK, ROBERT (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Bristol Bay Area Health Corporation | Dillingham, AK | $9.09M |
| Mental Health Center of Denver | Denver, CO | $8.43M |
| Mental Health Center of Denver | Denver, CO | $6.90M |
| Bristol Bay Area Health Corporation | Dillingham, AK | $6.80M |
| Bristol Bay Area Health Corporation | Dillingham, AK | $5.85M |
| Mental Health Center of Denver | Denver, CO | $1.98M |
| Robert a Clark MD Medical Corporation | Long Beach, CA | $572K |
| Mental Health Center of Denver | Denver, CO | $468K |
| Mental Health Center of Denver | Denver, CO | $414K |
| Clark Family Medicine PA | Newland, NC | $277K |
| Mental Health Center of Denver | Denver, CO | $183K |
| Mental Health Center of Denver | Denver, CO | $161K |
| Bristol Bay Area Health Corporation | Dillingham, AK | $152K |
| Bristol Bay Area Health Corporation | Dillingham, AK | $89K |
| Mental Health Center of Denver | Denver, CO | $88K |
| Mental Health Center of Denver | Denver, CO | $71K |
| Mental Health Center of Denver | Denver, CO | $63K |
| Clark Chiropractic INC | Englewood, OH | $63K |
| Mental Health Center of Denver | Denver, CO | $58K |
| Center for Primary Care PC | Evans, GA | $51K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.